Study provides new data about potential risk of gastric cancer in patients with intestinal metaplasia

Gastric cancer remains a significant problem globally. The relationship between intestinal metaplasia (IM) and gastric cancer has always been controversial. Generally IM is divided into subtypes on the basis of histochemical characteristics; however, this classification is confusing.

A new classification of IM is needed in order to follow up patients selectively. A research team led by Prof Zhang of the Department of Pathology, Qilu Hospital of Shandong University first proposed the classification of IM into SIM and AIM. The research project has won a Scientific Progress Award from the Board of Education, Shandong Province, China.

A research article to be published in January 21, 2010 in the World Journal of Gastroenterology lies in the novel classification of IM where IM is divided into simple IM (SIM) and atypical IM (AIM). And the data from the research indicated that AIM may be a precancerous lesion which could be a helpful indicator in the surveillance of patients clinically.

The authors regarded SIM as response to stimuli caused by the changing environment, while AIM may have malignant transformation and could be regarded as preneoplastic lesions.

The study provides important new data about the potential risk of gastric cancer in patients with intestinal metaplasia. However, it would be important in the future to investigate the expression of p53 and/or Her2Neu in a prospective study in patients with IM, to confirm that only patients with p53/Her2Neu expression in the IM have actually a higher risk for gastric cancers.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AI models redefine TIL scoring in breast cancer but face challenges in real-world validation